Skip to main content
Home > SciBX > Translational Notes

Chronological Index of : Translational Notes

 Current Issue
  • Buckets of money for the brain

    A few years ago, many companies threw in the towel on neurological diseases because poor understanding of their biology made R&D too risky. The field is finally receiving increased private and public funding, but some …

    Published on 9/11/2014
  • Table 1: Druggable projects

    Translational Notes: Funding forgotten proteins Table 1. Druggable projects. The NIH has allocated $5.8 million to fund 7 research projects that explore the biology of GPCRs, ion channels, kinases and nuclear …

    Published on 9/4/2014
  • Table 1: Allied Minds startups based in the life sciences

    Translational Notes: Meeting of the minds Table 1. Allied Minds startups based in the life sciences. Source: Allied Minds Startup Technology concept Products Origin of technology Biotectix LLC Next-generation …

    Published on 9/4/2014
  • Funding forgotten proteins

    A new NIH program is looking to fund understudied members of druggable protein classes by supporting exploratory projects at risk of being passed over because of a lack of preliminary data.

    Published on 9/4/2014
  • Meeting of the minds

    Allied Minds has partnered with Bristol-Myers Squibb to form Allied-Bristol Life Sciences LLC and can now add therapeutics to its portfolio of academia-based startups.

    Published on 9/4/2014
  • Table 1: Comparison of current awards to support nontraditional funding methods

    Translational Notes: Getting researchers off the grant treadmill Table 1. Comparison of current awards to support nontraditional funding methods. Source: NIH NIH Director's Awards National Cancer Institute …

    Published on 8/28/2014
  • Getting researchers off the grant treadmill

    The National Cancer Institute has created a generous seven-year award designed to ease the grant-writing burden for 'outstanding investigators'. Now the institute needs to ensure that the program is not just easier …

    Published on 8/28/2014
  • Industrial strength for Sanford-Burnham

    GSK executive Perry Nisen has joined Sanford-Burnham as CEO and plans to apply his industry know-how to accelerate drug development at the institute.

    Published on 8/28/2014
  • AstraZeneca taps the Cambridge wellspring

    AstraZeneca has unveiled plans for its R&D center and global headquarters in Cambridge, U.K. -- the next major step in the pharma's strategy to improve pipeline productivity to help it recover growth and regain ground …

    Published on 8/21/2014
  • Translational tidbits

    Astellas and Cancer Research UK team up to tackle autophagy in pancreatic cancer; the NIH bets big on bioelectronic therapeutics; a roundup of public-private partnerships.

    Published on 8/14/2014
  • Table 1: Selected public-private partnerships for July 2014

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for July 2014. In July, Intellimedix Inc. and Pfizer Inc. (NYSE:PFE) partnered with the Epilepsy Foundation to develop drug …

    Published on 8/14/2014
  • Translational tidbits

    Cold Spring Harbor Laboratory builds a quantitative biology center; the U.K. Medical Research Council expands its repurposing program, a drug-interaction database for histone methyltransferases; a roundup of recent …

    Published on 7/31/2014
  • Table 1: Nine starters from AstraZeneca

    Translational Notes: Translational tidbits Table 1. Nine starters from AstraZeneca. Through a 2011 partnership with AstraZeneca plc (LSE:AZN; NYSE:AZN), the Medical Research Council (MRC) awarded a total of £7 …

    Published on 7/31/2014
  • Table 2: Selected public-private partnerships for June 2014

    Translational Notes: Translational tidbits Table 2. Selected public-private partnerships for June 2014. In June, the U.K. made strong commitments to Alzheimer's disease (AD) and other forms of dementia via new public…

    Published on 7/31/2014
  • Dementia public-private partnerships

    Translational Notes: AD mission in the U.K. Table 1. Dementia public-private partnerships. Selected public-private partnerships focused on dementia research initiated over the past five years. Date Title Companies…

    Published on 7/24/2014
  • Dementia research initiatives in the U.K.

    Translational Notes: AD mission in the U.K. Table 2. Dementia research initiatives in the U.K. Select U.K.-based dementia research initiatives launched during the past year. Alzheimer's Research UK is contributing a …

    Published on 7/24/2014
  • AD mission in the U.K.

    The U.K. government is responding to calls for a dementia therapy by 2025 by securing nearly L120 million (US $205 million) from U.K.-based organizations for a series of research initiatives spanning discovery to the …

    Published on 7/24/2014
  • Table 1: Innovation Fund award recipients

    Translational Notes: Partnering in pediatrics Table 1. Innovation Fund award recipients. The Innovation Fund is managed by Cincinnati Children's Center for Technology Commercialization. Source: Cincinnati Children's…

    Published on 7/17/2014
  • Partnering in pediatrics

    Rare pediatric diseases are getting a boost from Alexion Pharmaceuticals, who recently announced a research collaboration with Cincinnati Children's Hospital Medical Center.

    Published on 7/17/2014
  • Translational tidbits

    Autism Speaks and Google partner on the world's largest collection of autism-related whole-genome sequence data; UCSF launches a project under the BRAIN initiative; a roundup of public-private partnerships.

    Published on 6/19/2014
  • Table 1: Selected public-private partnerships for May 2014

    Translational Notes: Translational tidbits Table 1. Selected public-private partnerships for May 2014. Last month, the University of California, San Francisco launched a project to identify brain signaling pathways …

    Published on 6/19/2014
  • CQDM: Canada on the brain

    The Quebec Consortium for Drug Discovery and Brain Canada have announced at least C$10 million (US$9.2 million) in funding for a new program to develop tools for pharma partners to accelerate the discovery of …

    Published on 6/12/2014
  • Table 1: Daiichi Sankyo's cardiovascular and endocrine/metabolic disease pipelines

    Translational Notes: Sanford-Burnham goes fourth Table 1. Daiichi Sankyo's cardiovascular and endocrine/metabolic disease pipelines. The therapies that Daiichi Sankyo Co. Ltd. (Tokyo:4568) has in its pipelines to …

    Published on 6/5/2014
  • Go west, FDA

    The FDA's first two centers for regulatory sciences were focused on modernizing methods and building bridges to academia. The agency now is at earlier drug development and has partnered with Stanford and UCSF to create …

    Published on 6/5/2014
  • Sanford-Burnham goes fourth

    The Sanford-Burnham Medical Research Institute has been seeking broader industrial partnerships that tap both its basic research and drug discovery expertise. Its new deal with Daiichi is the most expansive of its four …

    Published on 6/5/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993